Abstract 983P
Background
The HIMALAYA trial demonstrated that the efficacy of durvalumab (an PD-L1 inhibitor) is comparable to that of sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC), and its safety profile is more acceptable. The FOHAIC-1 study indicated that hepatic arterial infusion chemotherapy (HAIC) achieves better survival than sorafenib in advanced HCC with intrahepatic high-risk factors (i.e., Vp4 portal vein tumor thrombosis [PVTT]). This study aimed to evaluate the safety and efficacy of durvalumab plus HAIC as first-line therapy in pts with HCC with Vp3/4 PVTT.
Methods
The DurHope study was a single-arm, phase 2 trial. Eligible pts had HCC with Vp3/4 PVTT with no previous systemic treatment. Pts received HAIC of FOLFOX regimens (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) on day 1–3 plus durvalumab (1120 mg) intravenously on day 7 (±2) of each 21-day cycle for 8 cycles, followed by maintenance with durvalumab (1500 mg) every 28 days until disease progression, unacceptable toxicity, or death. The primary endpoint was 1-year overall survival (OS) rate. Secondary endpoints were progression-free survival (PFS), objective response rate (ORR) per RECIST v1.1, and safety.
Results
In this interim analysis, as of March 20, 2023, 19 pts who received at least one cycle of durvalumab and HAIC were included. The ORR was 47.4% (9/19) with 1 complete response and 8 partial response. The median time to response was 1.3 months (95% CI, 1.3–2.7), and the median duration of response was 5.4 months (95% CI, 3.7–5.8). The most common treatment-emergent adverse events (TEAEs) were hypoalbuminemia (18 [94.7%]), anaemia (17 [89.5%]), and neutropenia (16 [84.2%]). Grade 3/4 TEAEs occurred in 13 pts (68.4%). Two pts (10.5%) experienced grade 4 upper gastrointestinal bleeding.
Conclusions
Combination treatment with durvalumab and HAIC showed promising antitumor activity with ORR of 47.4% in HCC with Vp3/4 PVTT. Prophylactic gastrointestinal endoscope might be necessary to decrease the risk of gastrointestinal bleeding in such pts. Enrollment is ongoing and longer follow-up is needed to evaluate the survival data.
Clinical trial identification
NCT04945720.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18